Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Curaleaf Holdings Inc CURLF


Primary Symbol: T.CURA

Curaleaf Holdings, Inc. is an international provider of consumer cannabis products. The Company and its brands, including Curaleaf, Select, Grassroots, JAMS, Find and Zero Proof provide selection and accessibility across the medical and adult use markets. It operates in approximately 17 states and owns and operates 147 dispensaries and 21 cultivation sites with a focus on states, including Arizona, Florida, Illinois, Massachusetts, New Jersey, New York and Pennsylvania. It cultivates, processes, markets and/or dispenses a range of permitted cannabis products across its operating markets, including flower and pre-rolls, dry-herb vaporizer cartridges, concentrates for vaporizing such as pre-filled vaporizer cartridges and disposable vaporizer pens, concentrates for dabbing, such as mints, topical balms and lotions, tinctures, lozenges, capsules and edibles. Through Curaleaf International Holdings Limited, it has a supply and distribution network throughout the European market.


TSX:CURA - Post by User

Post by blackspade799on Jul 15, 2024 9:28am
55 Views
Post# 36132697

Older Patients Respond Favorably to Medical Cannabis

Older Patients Respond Favorably to Medical Cannabis

London, United Kingdom: Older patients report experiencing better health and well-being following their use of medical cannabis preparations, according to data published in the journal Drugs & Aging.

British researchers assessed the use of cannabis-based medicinal products (CBMPs) consisting of either flower or oil extracts in a cohort of patients ages 65 and older. (British specialists are permitted to prescribe cannabis products to patients unresponsive to conventional medications.) Study participants primarily suffered from chronic pain. Patients consumed cannabis products for three months.

Consistent with the findings of other observational studies, older patients reported “significant improvements” following cannabis use, including “substantial reductions” in pain severity.

https://norml.org/news/2024/06/27/study-older-patients-respond-favorably-to-medical-cannabis-products/

<< Previous
Bullboard Posts
Next >>